Altimmune (NASDAQ:ALT) Stock: Insider Gregory Weaver Acquires 10,000 Shares

Altimmune, Inc. (NASDAQ:ALT) CFO Gregory Weaver acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 13th. The shares were purchased at an average cost of $1.62 per share, for a total transaction of $16,200.00. Following the completion of the transaction, the chief financial officer directly owned 73,005 shares in the company, valued at $118,268.10. The trade was a 15.87% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Altimmune Stock Up 2.8%

NASDAQ:ALT traded up $0.04 on Friday, reaching $1.66. 3,501,696 shares of the stock traded hands, compared to its average volume of 4,245,085. The company has a market capitalization of $321.93 million, a price-to-earnings ratio of -2.12 and a beta of 0.16. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07. Altimmune, Inc. has a 12 month low of $1.58 and a 12 month high of $6.44. The company’s fifty day simple moving average is $2.62 and its 200 day simple moving average is $3.17.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Equities analysts predict that Altimmune, Inc. will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Evercore reaffirmed an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, September 21st. B. Riley Financial reissued a “buy” rating on shares of Altimmune in a report on Friday. Citigroup restated a “market outperform” rating on shares of Altimmune in a research note on Friday. Finally, HC Wainwright restated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and an average target price of $14.33.

Institutional Trading of Altimmune

A number of institutional investors have recently made changes to their positions in the stock. R Squared Ltd boosted its holdings in shares of Altimmune by 99.6% during the 3rd quarter. R Squared Ltd now owns 26,475 shares of the company’s stock valued at $76,000 after acquiring an additional 13,211 shares during the last quarter. StoneX Group Inc. purchased a new position in shares of Altimmune during the third quarter valued at approximately $46,000. Parallel Advisors LLC raised its holdings in shares of Altimmune by 21,755.0% during the third quarter. Parallel Advisors LLC now owns 8,742 shares of the company’s stock valued at $25,000 after purchasing an additional 8,702 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Altimmune by 29.6% during the third quarter. Alps Advisors Inc. now owns 255,875 shares of the company’s stock valued at $732,000 after purchasing an additional 58,501 shares during the last quarter. Finally, IPG Investment Advisors LLC purchased a new position in shares of Altimmune during the third quarter valued at approximately $29,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

More Altimmune News

These are some of the ALT news items that stood out recently:

• Positive Sentiment: New 48-week Phase 2b IMPACT data showed significant improvements in measures of liver fat, inflammation and fibrosis, alongside weight loss and generally favorable tolerability for investigational pemvidutide in MASH. The results were published in The Lancet Gastroenterology & Hepatology and support the ongoing Phase 3 PERFORMA trial. Article
• Positive Sentiment: Altimmune reported $480 million in cash, cash equivalents and investments at September 30, with a stated runway through the PERFORMA readout and into 2029—an important buffer for its clinical programs. Article
• Negative Sentiment: Third-quarter loss per share was $0.15, wider than the $0.13 consensus estimate. Higher research and development costs are pressuring results, and investors remain focused on the capital required to advance the pipeline despite the reported cash runway. Article

Altimmune Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.